JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab

JAMA Neurology

Volumn 71, Issue 5, 2014, Pages 596-602

  Frohman, Elliot M ^a   Monaco, Maria Chiara ^b   Remington, Gina ^a   Ryschkewitsch, Caroline ^b   Jensen, Peter N ^b   Johnson, Kory ^c   Perkins, Molly ^d   Liebner, Julia ^d   Greenberg, Benjamin ^a   Monson, Nancy ^a   Frohman, Teresa C ^a   Douek, Daniel ^d   Major, Eugene O ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; NATALIZUMAB; VIRUS ANTIBODY; VIRUS DNA;

ARTICLE; BLOOD SAMPLING; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA TEMPLATE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; JC VIRUS; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; VIREMIA;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD19; ANTIGENS, CD34; AOTIDAE; CELL LINE, TUMOR; DNA, VIRAL; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; JC VIRUS; LEUKOCYTES, MONONUCLEAR; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES;

EID: 84900472393     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.63     Document Type: Article

References (35)

1. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
2. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10(8):745-758.
3. Berger JR, Houff SA. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol. 2009;65(4):367-377.
4. Ransohoff RM. Natalizumab and PML [comment]. Nat Neurosci. 2005;8(10):1275.
5. Buckle GJ, Godec MS, Rubi JV, et al. Lack of JC viral genome sequences inMS brain tissue by polymerase chain reaction. Ann Neurol. 1992;32(6):829-831.
6. Bonig H,Wundes A, Chang KH, Lucas S, Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008;111(7):3439-3441.
7. Zohren F, Toutzaris D, Klrner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008;111(7):3893-3895.
8. Major EO. Reemergence of PML in natalizumab-treated patients: new cases, same concerns. N Engl J Med. 2009;361(11):1041-1043.
9. Houff SA, Major EO, Katz DA, et al. Involvement of JC virusinfected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med. 1988;318(5):301-305.
10. Tan CS, Dezube BJ, Bhargava P, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis. 2009;199(6):881-888.
11. Ryschkewitsch C, Jensen P, Hou J, Fahle G, Fischer S, Major EO. Comparison of PCRsouthern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J VirolMethods. 2004;121(2):217-221.
12. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2010;68(3):384-391.
13. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009;361(11):1081-1087.
14. Major EO,Miller AE, Mourrain P, Traub RG, de Widt E, Sever J. Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci U S A. 1985;82(4):1257-1261
15. Major EO, Vacante DA, Traub RG, LondonWT, Sever JL. Owl monkey astrocytoma cells in culture spontaneously produce infectious JC virus which demonstrates altered biological properties. J Virol. 1987;61(5):1435-1441.
16. Hamilton R, Gravell M, Major EO. Comparison of antibody titers by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol. 2000;38(1):105-109.
17. Jing D, Oelschlaegel U, Ordemann R, et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant. 2010;45(10):1489-1496.
18. Major EO, Frohman EM, Douek D. JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med. 2013;368(23):2240-2241.
19. Wei G, Liu CK, AtwoodWJ. JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J Neurovirol. 2000;6(2):127-136.
20. Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008;71(17):1350-1354.
21. SkaricaM, Eckstein C, Whartenby KA, Calabresi PA. Novel mechanism of immune modulation of natalizumab in multiple sclerosis. J Neuruoimmumology. 2011;235:70-76.
22. Planas R, Jel?i? I, Schippling S, Martin R, SospedraM. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol. 2012;42(3):790-798.
23. Warnke C, Smolianov V, Dehmel T, et al. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler. 2011;17(2):151-156.
24. Saure C,Warnke C, Zohren F, et al. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol. 2011;68(11):1428-1431.
25. Goodrum FD, Jordan CT, High K, Shenk T. Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc Natl Acad Sci U S A. 2002;99(25):16255-16260.
26. Poole E,McGregor Dallas SR, Colston J, Joseph RS, Sinclair J. Virally induced changes in cellular microRNAs maintain latency of human cytomegalovirus in CD34+ progenitors. J Gen Virol. 2011;92(pt 7):1539-1549.
27. AtwoodWJ, Amemiya K, Traub R, Harms J, Major EO. Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology. 1992;190(2):716-723.
28. Monaco MC, AtwoodWJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol. 1996;70(10):7004-7012.
29. Padgett BL,Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1(7712):1257- 1260.
30. Perkins M, Ryschkewitsch CF, Liebner JC, et al. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumabassociated progressive multifocal leukoencephalopathy. PLoS Pathog. 2012;8(11):e1003014. doi:10.1371/ journal.ppat.1003014.
31. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk. Ann Neurol. 2010;68(3):295-303.
32. Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ. JC virus antibody status underestimates infection rates. Ann Neurol. 2013;74(1):84-90.
33. Ryschkewitsch CF, Jensen PN, Major EO. Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants. J Clin Virol. 2013;57(3):243-248.
34. Major EO, Ryschkewitsch CF, Jensen PN, et al. Persistence of JCV in natalizumab treated MS patients who developed PML [reply]. Ann Neurol. 2011;69:430-431.
35. Sorenson PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(12):143-152.